Mainstay Medical has said the latest results from trials on its ReActiv8 product continue to show clinically important, statistically significant and lasting improvement in pain, disability and quality of life in patients.
ReActiv8 is an implantable neurostimulation system to treat chronic low back pain.
Dublin-listed medical devices firm Mainstay estimates that there are over two million people in the US and EU who could be candidates for treatment with ReActiv8.
The company said the additional results are consistent with those released by the company in August.
